Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological diseases. Its mission focuses on addressing the unmet needs of patients with conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Biogen's strategy emphasizes cutting-edge research, collaboration with academic institutions, and leveraging advanced technologies to enhance drug development. The company operates through a robust pipeline of therapies and a commitment to patient-centric solutions, aiming to improve the quality of life for individuals affected by debilitating neurological disorders.

BIOGEN INC

Biogen has recently reported its Q4 and full-year 2024 earnings on February 12, 2025, delivering a mixed bag that reflects both progress and challenges. The company's earnings surpassed expectations, recording a notable Q4 profit of $3.44 per share and a 3% revenue increase to $2.46 billion. However, this success is...

Biogen Reports Q4 Earnings Beat Amid Stock Decline and Cautious 2025 Outlook